What is an appropriate tapering strategy, with an example, for discontinuing inhaled corticosteroid therapy (e.g., fluticasone propionate) in a patient who has been using 250 µg twice daily for one year?

Tapering Strategy for Discontinuing Inhaled Corticosteroids

For patients on stable inhaled corticosteroid therapy (e.g., fluticasone propionate 250 µg twice daily for one year), reduce the dose by 25-50% every 1-3 months after demonstrating stable asthma control, rather than abrupt discontinuation.

Prerequisites Before Starting the Taper

Before attempting any dose reduction, confirm the following 1:

• Minimum 1-3 months of stability with minimal symptoms, no exacerbations, minimal need for rescue bronchodilators, and no activity limitations
• Lung function near normal (ideally PEF >75% predicted or personal best)
• Diurnal variability <25% and no nocturnal symptoms
• Verify compliance and proper inhaler technique before assuming the current dose is necessary

Recommended Tapering Protocol

Step-Down Approach

Reduce the ICS dose by 25-50% at each step 1. For your example of fluticasone propionate 250 µg twice daily:

1. First reduction: Decrease to 125-187.5 µg twice daily (or 100-125 µg twice daily if using available strengths)
2. Wait 1-3 months while monitoring for stability
3. Second reduction: If stable, decrease to 50-100 µg twice daily
4. Wait another 1-3 months
5. Final discontinuation: Only after demonstrating continued stability at the lowest dose

Monitoring During Taper

At each step, assess 1, 2:

• Symptom scores and rescue inhaler use (should remain <2-3 times daily)
• Peak flow measurements (maintain >75% predicted)
• Nocturnal awakenings (should remain minimal)
• Exacerbation frequency

If deterioration occurs at any step: Return to the previous dose that maintained control for 2-3 weeks, then attempt a slower taper 3.

Alternative Strategy: Fixed Low-Dose vs Step-Down

Research comparing step-down versus fixed low-dose strategies shows both approaches are similarly effective 4. A study demonstrated that stepping down from 1000 µg/day to 200 µg/day fluticasone was as effective as maintaining a fixed 200 µg/day dose for controlling bronchial hyperresponsiveness and eosinophilic inflammation. This suggests you could also consider:

• Directly reducing to a low maintenance dose (e.g., 100 µg twice daily) rather than gradual incremental reductions
• This may be appropriate for patients with well-controlled, mild-to-moderate asthma

Combination Therapy Considerations

If the patient is on combination ICS/LABA therapy (e.g., fluticasone/salmeterol), the evidence strongly favors 5:

• Reducing the ICS component while maintaining the LABA rather than switching to ICS monotherapy
• Example: Step down from fluticasone/salmeterol 250/50 µg to 100/50 µg twice daily, which maintains better control than switching to fluticasone 250 µg alone

Critical Pitfalls to Avoid

Timing and Seasonality

• Avoid tapering during high-risk periods: allergy season, respiratory infection season, or times of increased environmental exposure 2
• Consider patient age: Pediatric patients may require different considerations

Premature Discontinuation

• Never stop ICS abruptly in patients with moderate-to-severe asthma 1
• The 1-3 month stability period between reductions is essential—rushing the taper increases exacerbation risk 2

Inadequate Follow-Up

• Establish a clear action plan before each dose reduction 2
• Patients should know specific PEF values or symptom thresholds that trigger increasing treatment or seeking medical attention
• Schedule follow-up within 2-4 weeks after each dose reduction

Failure to Recognize Treatment Failure

If using >2-3 rescue inhalations daily or experiencing worsening symptoms, this indicates inadequate control—return to the previous effective dose 6.

When NOT to Taper

Do not attempt tapering if 1:

• The underlying disease requiring ICS is not controlled
• Patient is still experiencing frequent symptoms or exacerbations
• Rescue medication use is increasing
• Lung function is declining

Special Consideration: Short-Term ICS Use

For ICS therapy <3-4 weeks duration: No taper is necessary regardless of dose—can stop abruptly without concern for disease deterioration 7. This applies only to short courses, not your example of one-year therapy.

Practical Example for Your Scenario

Patient on fluticasone propionate 250 µg twice daily for one year:

Month 0-3: Continue current dose, verify stability (symptoms, PEF, rescue use)

Month 3: If stable, reduce to 125 µg twice daily (50% reduction)

Month 4-6: Monitor closely for deterioration

Month 6: If still stable, reduce to 100 µg twice daily (or 50 µg twice daily depending on available formulations)

Month 7-9: Continue monitoring

Month 9: If stability maintained, consider final reduction to 50 µg twice daily

Month 10-12: Assess for potential complete discontinuation only if all stability criteria maintained

This conservative approach minimizes exacerbation risk while achieving the goal of using the lowest effective ICS dose 1, 2.